United States securities and exchange commission logo





                              December 20, 2022

       John L. Lubniewski
       Chief Executive Officer
       HTG Molecular Diagnostics, Inc.
       3430 E. Global Loop
       Tucson, AZ 85706

                                                        Re: HTG Molecular
Diagnostics, Inc.
                                                            Registration
Statement on Form S-1
                                                            File No. 333-268681
                                                            Supplemental
Response dated December 20, 2022

       Dear John L. Lubniewski:

               We have reviewed your proposed amendments to the registration
statement and have the
       following comment. In our comment, we may ask you to provide us with
information so we may
       better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
December 16, 2022 letter.

       Supplemental Response filed December 20, 2022

       Potential Modification of Certain Outstanding Warrants, page 21

   1.                                                   We note the proposed
revised disclosure that, "[i]n connection with this offering, [you]
                                                        may amend the terms of
outstanding warrants" originally issued March 21, 2022, to
                                                        change the exercise
price and expiration date to coincide with those of the warrants in this
                                                        offering, as inducement
of the holder(s) of those warrants to participate in this offering.
                                                        Based on this
disclosure and the additional marked changed pages you provided
                                                        supplementally, it
appears you should revise this offering to include the registration of
                                                        these warrants and
identify the existing investor(s) who will receive the repriced warrants
                                                        in the offering. In
addition, tell us why the cost of the warrant repricing should not be
                                                        included as an offering
expense. Refer to Item 511 of Regulation S-K. Finally,
 John L. Lubniewski
HTG Molecular Diagnostics, Inc.
December 20, 2022
Page 2
      please provide the proposed changed pages you submitted earlier today
with your
      response, or under separate cover as correspondence in Edgar. We may have
additional
      comments.
      You may contact Benjamin Richie at 202-551-7857 or Abby Adams at 202-551-
6902 with any other questions.



                                                        Sincerely,

FirstName LastNameJohn L. Lubniewski                    Division of Corporation
Finance
                                                        Office of Industrial
Applications and
Comapany NameHTG Molecular Diagnostics, Inc.
                                                        Services
December 20, 2022 Page 2
cc:       Asa Michael Henin
FirstName LastName